AntiTIGIT drugs are direct inhibitors of T-cell proliferation and improve the anti-tumor immune response in many pre-clinical studies as a monotherapy or in combination with PD-1 and TIM-3 inhibitors. This evidence concerns the gene HAVCR2 and neoplasm.